Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team Day 1
MONDAY, APRIL 16, 2018 — Attending the full daily program will earn 6.75 contact hours (.675 CEUs). ACPE UAN 0860-0000-18-002-L01-P/0860-0000-18-002-L01-T (.675 CEUs)
What’s New in Organ Allocation and Distribution, Timothy L. Pruett, MD, University of Minnesota Health
Changes in organ allocation policies were intended to decrease waitlist mortality rates and increase organ availability for ill patients. Despite these changes, however, disparities still exist. This session will address how national policy impacts transplant access and organ availability and discuss the challenges of organ donation, access, and distribution.
Living Donation: Risks, Benefits and Long-Term Outcomes, Amit D. Tevar, MD, University of Pittsburgh Medical Center
Living organ donation clearly saves lives and presents an opportunity to help address the critical need for organ transplants. In some circumstances it reduces recipients’ waiting times and increases opportunities for patients without living donors to receive organs from deceased donors. There are, however, a series of ethical questions that arise with living donation that need to be addressed. This session will discuss the ethical issues surrounding living donation, including the risks, benefits and long-term outcomes for living donors.
Options for Advanced Heart Failure: Transplantation, Total Artificial Hearts and Mechanical Circulatory Support, Jaime D. Moriguchi, MD, Cedars-Sinai Heart Institute
Heart transplantation is the only curative therapy for chronic heart failure. However, the shortage of appropriate donor organs and the expanding pool of patients waiting for heart transplantation have led to growing interest in alternative strategies, including left-ventricular-assist-device (LVAD) therapy and total artificial hearts (TAHs). This session will describe the clinical use and long-term outcome of LVADs and discuss the challenges with assist devices as alternatives to transplantation. The use of the TAH as a bridge to transplant will also be reviewed
Lung Transplantation: Moving Towards a New Standard of Care, Gabriel Loor, MD, FACC, Baylor St. Luke's Medical Center
Lung transplantation has become standard therapy for patients with severe end-stage lung disease and pulmonary vascular disease. This session will discuss the epidemiology of lung transplant, donor selection, immunosuppressive therapies and complications of lung transplant. The standard of care will also be reviewed.
Precision Medicine in Cancer Care, Jonathan C. Trent, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami Health System
Precision medicine is defined by the tailoring of medical treatment to the individual characteristics of each patient and his/her disease. This session will discuss the role of precision medicine in cancer and highlight milestones in cancer therapy.
The Opioid Crisis and Its Effect on Transplant, Gregory J. McKenna, MD, FRCS(C), FACS, Baylor Scott & White Health
Organ donations have increased in the wake of America’s opioid epidemic. This session will address the opioid crisis and its effect on organ donation and transplantation.
The Future of Immunosuppression in Transplantation, Robert C. Harland, MD, FACS, Banner University Medical Center-Tucson
The guiding principle with immunosuppression in solid organ transplants is to achieve a balance between preventing rejection and avoiding side effects, which include various common and opportunistic infections and malignancies. This session will include a summary of immunosuppression and its future application in transplantation.
Current Disquiets of a Liver Transplant Surgeon, Michael Abecassis, MD, MBA, Northwestern University
This session will provide a glimpse into the thoughts, challenges and questions that occupy a transplant surgeon‘s mind as he or she continues to serve a growing population in need of organ transplantation.
- 6.75 ACPE - Pharmacists
- 6.75 ACPE - Pharmacy Technicians